Treatment of Group B Streptococcus Urinary Tract Infection in Non-Pregnant Patients

Diagnosis and Clinical Significance

• The urinalysis shows significant findings consistent with UTI: cloudy appearance, trace blood, trace protein, 2+ leukocyte esterase, and many bacteria, which is a significant finding in a symptomatic non-pregnant patient 1

Treatment Recommendations

• The American College of Radiology recommends penicillin G as the preferred agent due to its narrow spectrum of activity, with a dosing of 500 mg orally every 6-8 hours for 7-10 days, as stated by the Centers for Disease Control and Prevention 2, 3
• The Centers for Disease Control and Prevention recommends ampicillin as an acceptable alternative to penicillin, with a dosing of 500 mg orally every 8 hours for 7-10 days 2
• For penicillin-allergic patients, the Centers for Disease Control and Prevention recommends clindamycin, 300-450 mg orally every 8 hours, with susceptibility testing performed before use due to increasing resistance 3

Monitoring and Follow-up

• Follow-up urine culture after treatment completion may be warranted to ensure eradication, especially in patients with recurrent UTIs, as recommended by the Journal of the American College of Radiology 1

Treatment of Group B Streptococcus in Urine for Non-Pregnant Patients

Understanding GBS in Non-Pregnant Patients

• The Centers for Disease Control and Prevention recommends that non-pregnant adults with Group B Streptococcus in urine be treated according to standard urinary tract infection protocols only if they are symptomatic or have underlying urinary tract abnormalities, as stated in the MMWR Recommendations and Reports 4, 5

Treatment Approach for Non-Pregnant Patients

• The CDC guidelines state that symptomatic non-pregnant patients with GBS in urine should be treated according to standard UTI protocols, as recommended by the MMWR Recommendations and Reports 4
• The CDC guidelines for universal treatment of any concentration of GBS in urine apply specifically to pregnant women to prevent neonatal disease, and should not be applied to non-pregnant patients, as stated in the MMWR Recommendations and Reports 4, 6

Treatment of Group B Streptococcus in Urine (Non-Pregnant Patients)

Key Distinction from Pregnancy

• The Centers for Disease Control and Prevention (CDC) guidelines, as reported in MMWR Recommendations and Reports, mandate treatment of all GBS bacteriuria during pregnancy, but this does not apply to non-pregnant individuals, highlighting a critical distinction in treatment approaches between pregnant and non-pregnant patients 7, 8, 9

Clinical Context and Prevalence

• GBS accounts for a notable percentage of urinary tract infections in non-pregnant adults, with a significant proportion occurring in women, although the exact percentage is not specified in the provided citations 7, 8, 9

Treatment of Streptococcus agalactiae (Group B Streptococcus) UTI

Treatment Duration and Monitoring

• For complicated infections or when prostatitis cannot be excluded in men, the European Urology guidelines recommend extending treatment to 14 days 10

Special Considerations for Complicated UTI

• The European Urology guidelines suggest considering initial IV therapy with ampicillin 2 g IV every 4-6 hours, then transitioning to oral therapy once clinically stable, for patients presenting with systemic symptoms or complicated UTI 11
• The European Urology guidelines also recommend combination therapy with ampicillin plus an aminoglycoside for severe presentations 11
• The MMWR Recommendations and Reports guidelines suggest considering initial IV therapy with ampicillin 2 g IV every 4-6 hours, then transitioning to oral therapy once clinically stable, for patients presenting with systemic symptoms or complicated UTI 12

Management of GBS Bacteriuria in Non-Pregnant Patients

Key Clinical Distinctions

• In non-pregnant patients with Group B Streptococcus isolated from urine culture and normal urinalysis, no antibiotic treatment is indicated if the patient is asymptomatic, as this represents asymptomatic bacteriuria that should not be treated, according to the Infectious Diseases Society of America 13
• The management of GBS bacteriuria is fundamentally different between pregnant and non-pregnant patients, with all GBS bacteriuria requiring treatment at diagnosis plus intrapartum prophylaxis in pregnant patients due to the increased risk of neonatal disease, as recommended by the Centers for Disease Control and Prevention 14, 15

Evidence Against Treatment of Asymptomatic Bacteriuria

• The 2019 IDSA guidelines provide strong evidence against screening for or treating asymptomatic bacteriuria in most non-pregnant populations, including patients with diabetes, long-term care residents, and those with indwelling catheters, with the principle applying to GBS-specific ASB as well, indicating that absence of genitourinary symptoms means no treatment is warranted, based on strong evidence 13

Clinical Context: When GBS in Urine DOES Require Treatment

• Treatment would be appropriate if the patient had symptomatic UTI, abnormal urinalysis, underlying urinary tract abnormalities, or was pregnant, with any GBS in urine during pregnancy mandating treatment regardless of symptoms, as recommended by the Centers for Disease Control and Prevention 14, 15

Risk of Unnecessary Antibiotic Use

• Treating asymptomatic bacteriuria leads to unnecessary antibiotic exposure and resistance development, potential adverse drug effects without clinical benefit, and false reassurance that the pelvic pain has been addressed when the true cause remains unidentified, according to the Infectious Diseases Society of America 13 and the Centers for Disease Control and Prevention 14